SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SpringWorks Therapeutics (Nasdaq: SWTX) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference. The management presentation will be available on-demand starting September 13, 2021, at 7:00 am ET. Interested parties can access the webcast via the 'Events & Presentations' section on the company’s website. SpringWorks is focused on developing medicines for severe rare diseases and cancers, with a portfolio that includes 15 development programs and two lead candidates in late-stage clinical trials.
- None.
- None.
STAMFORD, Conn., Sept. 07, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference. A webcast of the company presentation will be available on-demand starting Monday, September 13, 2021 at 7:00 am ET.
To access the webcast, please visit the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.
About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology portfolio of small molecule product candidates and is advancing 15 development programs, including two potentially registrational clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to expand its portfolio and create more solutions for patients with cancer. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.
Contact:
Kim Diamond
Phone: 203-561-1646
Email: kdiamond@springworkstx.com
FAQ
When will SpringWorks Therapeutics present at the H.C. Wainwright Conference?
How can I access the SpringWorks Therapeutics conference presentation?
What is the focus of SpringWorks Therapeutics?
What programs does SpringWorks Therapeutics have in development?
What is the ticker symbol for SpringWorks Therapeutics?
